Reach Us +1-217-403-9671
Contract Research And Manufacturing Services (crams)-present Status In India | 7472
ISSN: 2167-7689

Pharmaceutical Regulatory Affairs: Open Access
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Contract research and manufacturing services (crams)-present status in India

2nd International Conference and Exhibition on Pharmaceutical Regulatory Affairs

Goundla Thejo ganesh Reddy

Posters: Pharmaceut Reg Affairs

DOI: 10.4172/2167-7689.S1.007

Contract research and manufacturing services (CRAMS) is one of the fastest growing segments in the pharmaceutical and biotechnology industry. The pharmaceutical market uses outsourcing services from providers in the form of contract research organizations (CROs) and contract manufacturing organizations (CMOs). Increasing costs of R&D, coupled with low productivity and poor bottom lines, have forced major pharmaceutical companies worldwide to outsource part of their research and manufacturing activities to low-cost countries like INDIA. India soffers significant cost advantages over mature manufacturing hubs in Europe and North America. India has already emerged as one of the leading cost-competitive and quality manufacturing hubs for many global players including big pharma companies. Moreover, the current economic crisis along with the continuous pricing pressure and pro-generic agenda are driving Pharma companies to leverage the strengths of Indian pharma manufacturers. The present study describes role of CRAMS, benefits & risks, present status in INDIA.
Goundla Thejo Ganesh Reddy is a student of JSS College of Pharmacy, JSS University, Ooty, Tamil Nadu, India. He has completed his B Pharm from JSS College of Pharmacy, Mysore during the year 2012. Presently he is pursuing M Pharm in Pharmaceutical Quality Assurance in JSS College of Pharmacy,Ooty. He has presented posters at national level and has attended various National and International Conferences. His current areas of interest are Quality Assurance, Regulatory Affairs, Quality Management Systems, analytical method development of novel drugs.